BACKGROUND:With the changing health scenario fungal infections have increased significantly, contributing to morbidity, mortality and health care cost. Candida is major human fungal pathogens that cause both superficial and deep tissue infections. With emergence of nonalbicans Candida species, availability of advanced identification methods and antifungal resistance, the spectrum of candidiasis has changed. OBJECTIVE: The aim of our study was to identify the distribution of Candida species among clinical isolates, risk factors associated with candidiasis and their sensitivity pattern for common antifungal drugs. MATERIALS AND METHODS: One hundred thirty nine different clinical isolates of Candida were collected from indoor patients of a tertiary care centre of Gujarat from May 2009 to June 2010. Identification of Candida species and antifungal susceptibility testing was performed with miniAPI (Analytical Prophylactic Index) (Biomerieux, France) which is an automatic identification and susceptibility testing instrument. RESULTS: We found that the non-albicans Candida were more prevalent than Candida albicans. Candida tropicalis (48.9%) was the most common Candida spp. and also more resistant than that of C.albicans. C.albicans showed resistance against fluconazole (3.5%) and itraconazole (8.8%) whereas C.tropicalis were resistant to amphotericin B (10.3%), fluconazole (20.7%), itraconazole (32.3%), and voriconazole (23.5%) and flucytosine (5.8%). Overall resistance rates of Candida for amphotericin B, fluconazole, itraconazole, and voriconazole and flucytosine were 6.4%, 15.2%, 22.3%, 12.9%, 5% respectively. CONCLUSION: To achieve better clinical results species-level identification of Candida spp. and their antifungal sensitivity testing should be performed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.